GSK-3β inhibitors were developed to treat neurodegenerative diseases such as AD, PD, bipolar disorder, and schizophrenia [13,14], but the long-term use of these inhibitors might disrupt many cellular processes because GSK-3β is a constitutively active kinase [15]. This evidence concerns the gene GSK3B and Parkinson disease.